Last Updated: 08 Nov 2024
Executive Summary
Syros Pharmaceuticals Inc. (SYRS) is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer and monogenic diseases. The company's stock has been under pressure in recent months, but the latest financial results and analyst recommendations suggest that it may be undervalued.
Company Overview
Syros Pharmaceuticals was founded in 2016 and is headquartered in Cambridge, Massachusetts. The company's mission is to develop innovative therapies that target the root cause of disease by modulating gene expression. Syros's lead product candidate, SY-5609, is a small molecule inhibitor of the bromodomain and extraterminal domain (BET) family of proteins. BET proteins are involved in regulating gene expression, and their inhibition has been shown to have therapeutic potential in a variety of diseases, including cancer and inflammation.
Fundamental Analysis
Syros Pharmaceuticals reported a net loss of $110.2 million for the fiscal year ended December 31, 2023. The company's revenue for the year was $386,000. Syros has a market capitalization of $68.7 million and a trailing price-to-sales ratio of 177.96.
Technical Analysis
The technical analysis of Syros Pharmaceuticals' stock shows that the stock has been in a downtrend since early 2023. The stock's 50-day moving average is $1.972, and its 200-day moving average is $4.673. The stock's relative strength index (RSI) is 34.5, which indicates that the stock is oversold.
Short Term Outlook
The short-term outlook for Syros Pharmaceuticals' stock is mixed. The stock's technical analysis suggests that the stock could continue to decline in the near term. However, the company's recent financial results and analyst recommendations suggest that the stock could be undervalued.
Long Term Outlook
The long-term outlook for Syros Pharmaceuticals' stock is positive. The company's lead product candidate, SY-5609, has shown promising results in clinical trials. If SY-5609 is approved by the FDA, it could be a major commercial success for Syros.
Analyst Recommendations
The consensus analyst rating for Syros Pharmaceuticals' stock is "Buy." Five analysts recommend buying the stock, while zero analysts recommend selling the stock. The average analyst target price for the stock is $8.75.
Conclusion
Syros Pharmaceuticals is a clinical-stage biopharmaceutical company with a promising pipeline of drugs. The company's stock has been under pressure in recent months, but the latest financial results and analyst recommendations suggest that it may be undervalued. Investors should consider adding Syros Pharmaceuticals to their watchlists.
